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Zygomycosis in neutropenic patients with
past Aspergillus infection: a role for
posaconazole?
In the March 2004 supplement of Clinical Micro-
biology and Infection, Donnelly and De Pauw [1]
published a review on voriconazole, with empha-
sis on its use for treating cases of candidosis,
invasive aspergillosis, and some more uncommon
mycoses caused by Scedosporium spp. and
Fusarium spp. Voriconazole has little activity
against Sporothrix schenckii and zygomycetes such
as Mucor spp., Rhizopus spp. and Absidia spp. [1].
Thus, selective pressure from prolonged courses
of voriconazole, or increased survival among
profoundly immunosuppressed patients, may
explain the higher incidence of zygomycosis in
patients who remain at obvious risk for invasive
fungal infections [2].
Marty et al. [2] have described breakthrough
zygomycoses in recipients of allogenic haemato-
poietic stem-cell transplants since the introduction
of voriconazole, and we would like to report a
similar case of a man aged 65 years, diagnosed
with acute myeloid leukaemia, who received vor-
iconazole for proven neutropenia-induced inva-
sive pulmonary aspergillosis (i.e., respiratory
samples positive ondirect examination and culture
for Aspergillus fumigatus; serum galactomannan
positive on several occasions; compatible thorax
lesions visualised by computerised tomography
scan). While receiving voriconazole, the patient
developed a massive maxillary and ethmoidal
sinusitis, with proptosis of the right eye showing
hyphal elements on direct examination of tissue
samples. Culture remained sterile. Therapy was
altered to amphotericin B, but persistence of the
lesions prompted a Caldwell–Luc debridement.
Tissue samples nowrevealed fungal elements, seen
typically in cases of zygomycosis, comprising
thick-walled, aseptate right-angle branching fila-
ments (Fig. 1) [3]. Culture yielded no growth. The
patient’s therapy was changed to oral posaconaz-
ole 800 mg daily [4,5]. The patient recovered and
continues to receive posaconazole 400 mg daily
without major side effects.
We conclude that posaconazole is a potentially
useful therapy for patients developing break-
through zygomycosis after long-term use of voric-
onazole.Agood responsehas alreadybeen reported
in a case of invasive aspergillosis treated with
posaconazole [6], but it is not yet clear whether this
drug is appropriate for the first-line treatment of
non-Candidamycoses in these patients.
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